Issue No. 2 · Week of August 24, 2026
This week brought real movement on both fronts that matter most to you. The US-Canada tariff standoff finally broke, with 50 percent tariffs on Canadian goods taking effect August 22 and Canada confirming retaliation for September 8, while FDA got a new commissioner nominee and opened the door to generative AI enabled devices.
If you sell into North America, this is a good week to review your tariff exposure and watch how the FDA leadership change plays out over the coming weeks.
Hospitals and Health Systems
Bon Secours Mercy Health to acquire its 48th hospital
Bon Secours Mercy Health, through its HealthSpan Partners subsidiary, is acquiring Fauquier Health, a 97 bed hospital in Warrenton, Virginia, from Lifepoint Health, with the deal expected to close in fall 2026 and the facility converting to nonprofit status. It is another example of continued hospital consolidation into larger systems, which keeps concentrating purchasing authority in fewer corporate offices that a foreign manufacturer needs to reach and stay credentialed with.
Source: Becker’s Hospital Review – August 21, 2026
Construction underway on 2.6 billion dollar hospital west of Montreal
The new Vaudreuil-Soulanges hospital, a 404 bed facility with 11 operating rooms and a 2.6 billion dollar budget, is under construction in Quebec’s underserved Monteregie-Ouest region, targeted for completion in summer 2027 and gradual opening through summer 2028. Large new builds like this represent a multi-year window for equipment and device vendors to get on the procurement radar well before opening day, though the project’s own hiring shortfall of doctors and staff is a reminder that timelines on Canadian hospital construction can slip.
Federal Health Systems: VA and DoD
VA raises Oracle Health EHR contract ceiling to nearly 27 billion dollars
The Department of Veterans Affairs added 16.9 billion dollars to its Oracle Health electronic health record contract, raising the ceiling to 26.9 billion dollars and extending the performance period through May 2031, with 14 VA sites live and 36 more scheduled through January 2028. The move signals the VA is committed to its current EHR vendor and deployment timeline for years to come, which matters to any manufacturer whose devices or interfaces need to integrate with VA’s clinical systems or who sells into VA facilities on that rollout schedule.
Regulatory: FDA and Health Canada
Trump nominates Heidi Overton to lead FDA
President Trump moved to nominate Heidi Overton, a physician and current deputy assistant to the president for domestic policy, as FDA commissioner, to replace acting commissioner Kyle Diamantas after Marty Makary’s departure. She still needs Senate confirmation through a hearing led by Senator Bill Cassidy, whose relationship with the administration has been strained over vaccine policy disagreements. A new commissioner after a period of resignations and leadership turnover at FDA is worth watching for any device manufacturer, since it can shift review priorities, staffing and the pace of guidance and submissions across the agency.
Source: Medical Device Network – August 18, 2026
FDA seeks public feedback on regulatory approach for generative AI enabled medical devices
FDA issued a discussion paper proposing a two axis risk framework and a competency assessment model for premarket review of generative AI enabled devices, including foundation models and agentic AI systems, and is taking public comment through docket FDA-2026-N-7874 until October 19. Any manufacturer building AI features into its devices, or planning to, should treat this as an early look at where FDA’s evidence and testing expectations are heading and consider submitting comments.
Source: U.S. Food and Drug Administration – August 18, 2026
CMS proposes a same day Medicare coverage pathway for breakthrough devices
CMS proposed a new Regulatory Alignment for Predictable and Immediate Device, or RAPID, pathway that would let a national Medicare coverage determination issue the same day as FDA market authorization for certain breakthrough devices, with coverage able to start as soon as 60 days after approval, down from an average of nearly five years today. For a foreign manufacturer with a breakthrough designated device, a faster and more predictable path from FDA clearance to Medicare reimbursement could meaningfully shorten the time to first US revenue.
Source: CMS – August 11, 2026
BD’s intraosseous needle recall reaches Canada’s recall database
The BD intraosseous vascular access needle set recall, tied to an out of tolerance obturator defect and four US deaths, has now also surfaced in Health Canada’s recall database under Bard Access Systems for the same Needle Kit For Powered Driver product family, classified as Health Canada’s most serious Type I recall. It is a concrete example of how a single manufacturing defect can trigger parallel but separately timed recall actions in the US and Canadian systems, something any manufacturer selling into both markets needs to track and report on two independent regulatory timelines.
Source: FDA / Health Canada – August 15, 2026
Import, Customs and Trade
50 percent US tariffs on Canadian goods took effect August 22 after trade talks collapsed, Canada to retaliate September 8
The Section 338 tariffs flagged in prior weeks were paused for three days while the US and Canada tried to reach a broader trade deal, but when those talks broke down and Prime Minister Mark Carney recalled Canada’s negotiating team, the 50 percent duties on roughly 554 Canadian tariff lines took effect as scheduled at 12:01 a.m. ET on August 22. Canada has announced dollar for dollar retaliatory tariffs on steel, dairy, appliances, agricultural equipment, pulp and paper, and electronics starting September 8, and USMCA preferential treatment does not shield the covered goods from these duties.
Medical devices are still not named on either country’s list, but any manufacturer with cross border supply chains should keep watching this dispute, since the covered categories have already expanded once and retaliation is now confirmed rather than threatened.
Also Noted
Baxter Duo-Vent IV Solution Set Recall
Baxter’s Duo-Vent IV solution sets were classified as a Class I recall after reports that trapped air bubbles could cause stroke, tissue damage or death.
Fitch Warns Nonprofit Hospital Margin Recovery May Have Peaked
Fitch Ratings warned that nonprofit hospital margin recovery may have peaked in 2025, with weaker Medicaid dependent hospitals especially exposed as federal budget cuts start hitting providers in 2027, a signal of continued price pressure on device and instrument purchasing.
Source: Healthcare Dive
Cyberattacks Continue to Hit Medical Device Manufacturers
MedTech Dive’s roundup of 2026 cyberattacks on device makers, including Stryker’s Microsoft environment compromise, an Intuitive Surgical phishing attack and an Abbott breach, is a reminder that a foreign manufacturer’s own IT environment and vendor access points deserve the same scrutiny as its products.
Source: MedTech Dive
Key Takeaways for Medical Device Manufacturers
This week’s developments reinforce three areas for manufacturers selling into the U.S. and Canadian markets: monitor cross border tariff exposure as the U.S.-Canada trade dispute develops, watch FDA leadership and emerging regulatory expectations for generative AI enabled devices, and prepare for changes that could accelerate Medicare coverage for qualifying breakthrough devices.
Manufacturers operating in both countries should also maintain separate recall monitoring processes for FDA and Health Canada, while companies supplying hospitals should continue watching consolidation, major capital projects and financial pressures that can influence procurement decisions.
Questions About U.S. or Canadian Market Access?
Dawa Medical supports foreign medical device manufacturers entering the U.S. market as U.S. Agent, FDA Initial Importer and Importer of Record, with 3PL warehousing and regulatory compliance support. Through TB Medical Inc., manufacturers can also access Canadian importation and distribution support.
About The Access Brief: The Access Brief summarizes publicly reported news affecting medical device manufacturers selling into the United States and Canada and reflects Dawa Medical’s own understanding. It is not legal, regulatory or binding advice, and formal advice should come from qualified counsel or a specialist consultant.
